Blockchain Registration Transaction Record

Quantum BioPharma Taps Thermo Fisher for Phase 2 MS Trial

Quantum BioPharma partners with Thermo Fisher to launch Phase 2 trial of Lucid-MS, a novel MS therapy targeting myelin repair, offering hope for progressive MS patients.

This news matters because it signals a potential paradigm shift in multiple sclerosis treatment. Current therapies primarily suppress the immune system, but Lucid-MS targets the underlying myelin damage that drives disease progression—a mechanism that could finally address the urgent unmet needs of progressive MS patients, who currently have few effective options. By partnering with Thermo Fisher, a global leader in CNS trials, Quantum BioPharma is positioning Lucid-MS for rigorous clinical evaluation. If successful, this approach could not only slow disability but also repair existing damage, transforming the lives of millions living with MS. The trial's start-up also represents a crucial step toward bringing a first-in-class therapy to a market projected to exceed $38 billion by 2030, offering hope to patients and potential value to investors.